FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity

https://www.fda.gov/news-events/fda-voices/fda-focuses-closing-clinical-trial-reporting-gap-research-integrity?utm_medium=email&utm_source=govdelivery FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity Clinical trial transparency is fundamental to maintaining public trust in medical research and supports broader scientific advancements among the global clinical research community. The U.S. Food and Drug Administration is keenly focused on clinical trial transparency, which is an ethical obligation under the Declaration of Helsinki and rooted in the fundamental principles of medical research. The Declaration of Helsinki establishes ethical principles for medical research involving human subjects and serves as a cornerstone document for the international medical community, providing guidance on issues such as informed consent and the protection of vulnerable populations in clinical trials. This declaration emphasizes that data transparency is essential for enabling scientific advancements and protecting research participants' rights and well-being.